Researchers are invited to submit abstracts for presentation at SOLAR, a scientific meeting focused on advances in steatotic liver disease, obesity, and related metabolic liver disorders. Accepted abstracts will be presented as posters, with a limited number selected for oral presentations.

• Poster Presentations: All accepted abstracts will be presented as posters.
• Oral Presentations: Five (5) top-scoring abstracts will be selected for oral presentation based on scientific merit, novelty, and clinical relevance.

• Clinical Epidemiology – Steatotic Liver Disease, Obesity, Cholestasis, Viral, and Metabolic Liver Disease
• Diagnostic Procedures – Steatotic Liver Disease and Liver Fibrosis
• Therapeutic Trials – Steatotic Liver Disease, Cholestatic Liver Disease, Viral hepatitis, Obesity, and Liver Fibrosis (Humans)
• Clinical Trial Design
• Disease Management of Steatotic/Viral/Cholestatic Liver Disease and Metabolic Comorbidities
• Obesity and Metabolic Dysfunction in Liver Disease
• Pharmacoeconomic and Societal Aspects
• Real-World Evidence and Outcomes Research
• Experimental/Basic Science – Liver Disease and obesity (Non-human)
• Pathogenesis and Translational Science – Liver Disease and Liver Fibrosis (Humans)
• Pharmacology and Emerging Therapeutics
• Non-Invasive Testing and Biomarkers
• Imaging and Digital Health in Liver Disease
• Pediatric Steatotic Liver Disease and Obesity
• Clinical trials of anti-obesity medications
• Bariatric surgery clinical outcomes
• Endoscopic or device-based obesity therapies
• Weight loss effects on cardiometabolic risk factors
• Obesity and type 2 diabetes outcomes
• Obesity and liver disease (MASLD/MASH) outcomes
• Body composition and metabolic changes with treatment
• Real-world effectiveness and safety of obesity therapies
• Lifestyle and structured weight management interventions
• Obesity-related comorbidities and clinical outcomes

• Clinical trials (all phases)
• Observational and real-world studies
• Translational research
• Diagnostic and biomarker studies
• Health outcomes and pharmacoeconomic research
• Basic and preclinical science

• Industry-sponsored and investigator-initiated studies are permitted.
• Studies involving investigational therapies are allowed.

• Encore abstracts must be clearly identified at submission.
• Eligible for poster presentation.
• Not eligible for awards or oral presentation unless they include substantial new data, at Course Director discretion.

• Recently completed clinical trials
• Practice-changing data
• Major safety or efficacy findings
• High-impact translational results

Late-breaking abstracts may be selected for poster or oral presentation at Course Director discretion.

Maximum 500 words (excluding title and authors).

• Abstract Submission Opens: March 6, 2026
• Abstract Submission Deadline: June 5, 2026
• Acceptance Notifications: June 12, 2026

• At least one author must register for the meeting.
• Poster presenters must be present during assigned poster sessions.
• Oral presenters must adhere to assigned presentation times.